News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SIDMAP Hires Fred Siegman, Ph.D. As New Vice President Of Sales And Marketing


10/19/2005 5:12:38 PM

LOS ANGELES, Feb. 7 /PRNewswire/ -- SIDMAP, the leading provider of tracer-based dynamic metabolic profiling services, has hired Fred Siegman, Ph.D. to head its growing sales team. Dr. Siegman has over 20 years of experience selling and marketing a wide range product technologies and services to the pharmaceutical and biotech industry. Previously, Dr. Siegman held the position of Senior Product Manager at QIAGEN, Inc., overseeing the company's RNA research product line in North America. Dr. Siegman will take over the sales and business development duties from David Manheim, SIDMAP's Vice President of Business and Legal Affairs. Mr. Manheim will continue as SIDMAP's Vice President of Operations and General Counsel.

"We are extremely pleased that Fred has decided to join our team" said Agi Hirsberg, President and Founder of SIDMAP, "His doctoral work in biochemistry and extensive experience providing support services to life science, biotech and pharmaceutical companies, was exactly what we were looking for."

"SIDMAP is well positioned in the emerging field of Metabolomics," said Dr. Siegman. "I was impressed with the passion and vision of the SIDMAP team as well as the unique technology they have developed."

About SIDMAP

SIDMAP is a service based consulting and drug-testing company with exclusive expertise in applying stable isotope tracer methodologies to acquire detailed understanding of human diseases and drug effects at the nano-scale level. The company uses its unique scientific expertise and technology in partnership with biomedical research and pharmaceutical companies to accelerate the drug discovery process and illuminate the pathway to greater discoveries. Stable isotope-based dynamic metabolic profiling provides researchers and drug developers with the data they need to make more informed decisions concerning the validity of potential drug targets and the efficacy of drug candidates. The company also provides life science and biotech Venture Capitalists with the necessary biological due diligence to make sound investments. SIDMAP is headquartered in Los Angeles, Calif.

SIDMAP

CONTACT: David Manheim of SIDMAP, +1-310-476-0270, dmanheim@sidmap.com


Read at BioSpace.com


comments powered by Disqus
SIDMAP
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES